Pfizer Gets Positive Data in EU Trial for 20-Valent Pneumococcal Vaccine

Pfizer has reported promising results from an EU late-stage trial supporting the use of its 20-valent pneumococcal vaccine in infants. The results will be used in Pfizer’s filing of the vaccine with the European Medicines Agency, which is expected to be completed by the end of 2022.  This news comes just over a month after the company reported results from a similar trial in the US.

According to Kyle LaHucik, “The US study tested four doses. Regarding the differences in number of shots between the two regions, Pfizer said in an email to Endpoints News that Europe’s regulators’ immunization schedule looks at two infant doses and one toddler dose for pneumococcal conjugate vaccines. However, the recommendation for some vulnerable infants remains four overall doses, depending on the country, the spokesperson said. The four dose series in the US reflects the FDA and ACIP recommended schedule, they added.”

To read more, click here.

(Source: Endpoints News, September 19^th, 2022)